SNCA, a novel biomarker for Group 4 medulloblastomas, can inhibit tumor invasion and induce apoptosis

Yong-Xiao Li1 | Zhen-Wei Yu1 | Tao Jiang2 | Li-Wei Shao1 | Yan Liu1 | Na Li1 | Yu-Feng Wu1 | Chen Zheng1 | Xiao-Yu Wu1 | Ming Zhang1 | Dan-Feng Zheng1 | Xue-Ling Qi3 | Min Ding4 | Jing Zhang1,5 | Qing Chang1

1Department of Pathology, Peking University School of Basic Medical Science, Peking University Third Hospital, Peking University Health Science Center, Beijing, China
2Department of Neurosurgery, Beijing Tiantan Hospital, Beijing, China
3Department of Pathology, Beijing Sanbo Brain Hospital, Beijing, China
4Department of Pathology, Anhui Provincial Hospital, Hefei, China
5Department of Pathology, University of Washington, Seattle, WA, USA

Correspondence
Qing Chang, Department of Pathology, Peking University School of Basic Medical Science, Peking University Third Hospital, Peking University Health Science Center, Beijing, China.
Email: qingchang@bjmu.edu.cn

Funding Information
National Natural Science Foundation of China; Peking University Third Hospital, Peking University Health Science Center.

Medulloblastoma (MB) is the most common malignant brain tumor in childhood. It contains at least four distinct molecular subgroups. The aim of this study is to explore novel diagnostic and potential therapeutic markers within each subgroup of MB, in particular within Group 4, the largest subgroup, to facilitate diagnosis together with gene therapy. One hundred and six MB samples were examined. Tumor subtype was evaluated with the NanoString assay. Several novel tumor related genes were shown to have high subgroup sensitivity and specificity, including PDGFRA, FGFR1, and ALK in the WNT group, CCND1 in the SHH group, and α-synuclein (SNCA) in Group 4. Knockdown and overexpression assays of SNCA revealed the ability of this gene to inhibit tumor invasion and induce apoptosis. Methylation-specific PCR and pyrosequencing analysis showed that epigenetic mechanisms, rather than DNA hypermethylation, might play the key role in the regulation of SNCA expression in MB tumors. In conclusion, we identify SNCA as a novel diagnostic biomarker for Group 4 MB. Some other subgroup signature genes have also been found as candidate therapeutic targets for this tumor.

KEYWORDS
biomarker, medulloblastoma, molecular subtype, SNCA, tumor invasion

INTRODUCTION

Medulloblastoma (MB) is the most common malignant brain tumor in childhood. A multimodal treatment strategy, with surgical resection followed by radiotherapy and chemotherapy, has improved the overall 5-year survival rate to >80%, but the prognosis for patients with recurrent MB remains very poor; patients with areas of frank dissemination had a low 5-year event-free survival rate of approximately 36%.1,2

There is now a consensus, based on current studies, including our recent results, that MB is not a single tumor, but is rather a heterogeneous group of tumors that differ not only in histologic appearance, but also in molecular biology. Medulloblastoma can be divided into at least four clinically, transcriptionally, and genetically distinct molecular variants.3-5 These include the WNT and SHH groups of tumors, which show overexpression of regulators and target genes in the WNT and SHH signaling pathways, respectively.6

1 | INTRODUCTION

Medulloblastoma (MB) is the most common malignant brain tumor in childhood. A multimodal treatment strategy, with surgical resection followed by radiotherapy and chemotherapy, has improved the overall 5-year-survival rate to >80%, but the prognosis for patients with recurrent MB remains very poor; patients with areas of frank dissemination had a low 5-year event-free survival rate of approximately 36%.1,2

There is now a consensus, based on current studies, including our recent results, that MB is not a single tumor, but is rather a heterogeneous group of tumors that differ not only in histologic appearance, but also in molecular biology. Medulloblastoma can be divided into at least four clinically, transcriptionally, and genetically distinct molecular variants.3-5 These include the WNT and SHH groups of tumors, which show overexpression of regulators and target genes in the WNT and SHH signaling pathways, respectively.4
Group 3 tumors, in which most tumors show MYC amplification and the worst prognosis, and Group 4 tumors, which is the largest subgroup of MB.\(^4\) Subgroup-specific markers to facilitate diagnosis together with precision gene therapy have thus become a critical area in next-generation clinical trials for MB.

Although Group 4 is the largest subtype of MB (up to 30% of tumors),\(^6\) its molecular pathogenesis is the least well understood. The genetic and epigenetic foundations of this group and their clinical significance is incompletely understood.\(^7-9\) Our previous studies showed that MB is an epigenetic disease.\(^5,10,11\) MicroRNA (miR)-449a was identified as a potential epigenetic marker of the Wnt subgroup.\(^5\) However, so far, there are few adequately characterized group-specific epigenetic markers for Group 4.

Our aim was to integrate more potential subtype-specific biomarkers for each subgroup of MBs, especially for Group 4, into the NanoString platform to improve diagnosis efficiency and to find novel therapeutic targets for this tumor. Based on our preliminary result and the criteria in the new WHO classification on MB,\(^3,5\) the customized CodeSet with 11 cancer-related genes and 22 well-characterized group-specific genes were included for the present study.

2  |  MATERIALS AND METHODS

2.1  |  Clinicopathologic information

Formalin-fixed, paraffin-embedded samples were obtained from 106 MB in patients from the Third Hospital of Peking University, the Beijing Tiantan Hospital, the Beijing Sanbo Brain Hospital (all Beijing, China), and the Anhui Provincial Hospital (Hefei, China). Tumor samples were collected between September 2009 and December 2011. Each tumor was reviewed by two pathologists (QC and YFZ) independently, and results were merged. Demulloblastomas were histologically classified as classic, desmoplastic nodular, extensive nodular, or large cell/anaplastic variants according to the 2016 WHO classification.\(^2\) The MBs used in this study (n = 106) included 56 classic MBs (52.83%), 30 desmoplastic nodular MBs (28.30%), 10 extensive nodular MBs (9.43%), and 10 large cell/anaplastic (9.43%) variants. The mean age of these patients was 8.0 years in 90 children, and 33.4 years in 16 adults. Clinicopathologic information is summarized in Table 1. This study was approved by the Institutional Review Board of Peking University (review reference no. IRB00001052-14003).

2.2  |  Candidate gene selection

Gene expression analysis was carried out using the classic MB subtyping gene CodeSet, which included 22 well known signature genes for different subgroups,\(^5,12\) as well as 11 additional tumor-related genes. Six of the tumor-related genes (ALK, MYCN, TP53, GLI1, MYC, and SNCAIP) have been reported to be related with different subtypes of this malignant brain tumor, based on various technical assays, and were integrated into the CodeSet here to improve the efficiency of clinical molecular testing as well as strengthen the subtyping fidelity of the NanoString platform.\(^7,13-18\) In addition, some candidates for therapeutic targets of this tumor, which were screened by our previous study (data not shown), were recruited in the current panel of genes, such as FGFR1, PDGFR\(\alpha\), and CCND1.\(^19-24\) The relationship between these genes and tumor subtyping need to be further elucidated. HNF4\(\alpha\), which was recently found to be a specific protein marker in exosomes from supernatant of an MB cell line,\(^25\) as well as SNCA, which encodes \(\alpha\)-synuclein, an interactive protein of synphilin-1, which is encoded by SNCAIP,\(^13\) were also included in this study.

2.3  |  RNA isolation and NanoString analysis

Total RNA from formalin-fixed, paraffin-embedded sections extracted from 75 MB samples were analyzed based on the NanoString nCounter Analysis System (NanoString Technologies, Seattle, WA, USA) in the Department of Pathology, Peking University Health Science Center (Beijing, China). All procedures related to mRNA quantification, including sample preparation, hybridization, detection, and scanning, were carried out as previously described.\(^5\) RNA concentration was measured by Qubit (Thermo Fisher). All samples consisted of at least 80% of tumor cells. Normalization of the raw NanoString data was undertaken using nSolver Analysis Software version 2.5 (NanoString Technologies).\(^12\) All statistical analyses were carried out with the R statistical programming environment (version 3.1.1). The Kruskal–Wallis test was used to correlate tumor type and gene expression. The experiment was repeated twice.

2.4  |  Immunohistochemistry

Formalin-fixed, paraffin-embedded sections from 93 MB were reviewed. Immunohistochemistry (IHC) staining was carried out using \(\alpha\)-synuclein primary mAb (1:1500; 610787; BD Biosciences, San Jose, CA, USA). Staining patterns of \(\alpha\)-synuclein were assessed by two neuropathologists (QC and YFZ) independently, and results were merged to a consensus score. Briefly, the proportion of cells with strong \(\alpha\)-synuclein immunoreactive staining in the cell cytoplasm and/or nucleus in the total tumor area was estimated for each patient.\(^26\) Absence of staining or weak staining was scored as zero. Red blood cells in tumor vessels served as the positive internal control.

2.5  |  Demethylation treatment of MB cell lines

Three MB cell lines (Daoy, D283, and D341) obtained from the ATCC (Manassas, VA, USA) were treated with 5-aza-2’-deoxycytidine as previously reported,\(^27\) and tested for restoration of SNCA gene expression with real-time PCR.

2.6  |  Sodium bisulfite treatment of DNA followed by methylation-specific PCR and pyrosequencing for detection of SNCA promoter methylation in primary MB

Genomic DNA from MB cell lines were treated with sodium bisulfite using the BsilFlash DNA Modification Kit (EpiGentek, Farmingdale,
TABLE 1  Clinicopathologic information of 106 medulloblastomas (MB)

| Case no. | G  | A  | His | Mol | IHC (%) | MSP | Case no. | G  | A  | His | Mol | IHC (%) | MSP |
|----------|----|----|-----|-----|---------|-----|----------|----|----|-----|-----|---------|-----|
| MB11     | F  | 5  | C   | WNT | 0       | U   | MB39     | M  | 5  | N/D | Group 4 | 10    | NA   |
| MB20     | F  | 18 | C   | WNT | 0       | Me  | MB71     | M  | 7  | C   | Group 4 | 10    | NA   |
| MB3      | F  | 13 | C   | WNT | 3       | NA  | MB1      | M  | 4  | N/D | Group 4 | 20    | U    |
| MB3      | F  | 52 | N/D | WNT | 5       | M   | MB42     | M  | 7  | N/D | Group 4 | 30    | NA   |
| MB18     | F  | 14 | N/D | WNT | 5       | NA  | MB52     | M  | 11  | EN  | Group 4 | 30    | NA   |
| MB75     | F  | 13 | C   | WNT | 10      | NA  | MB74     | M  | 4  | C   | Group 4 | 35    | NA   |
| MB66     | F  | 26 | L/A | WNT | NA       | NA  | MB15     | F  | 9  | C   | Group 4 | 40    | U    |
| MB68     | F  | 13 | C   | WNT | NA       | NA  | MB13     | M  | 22  | C   | Group 4 | 60    | U    |
| MB2      | F  | 33 | C   | SHH | 0       | U   | MB36     | M  | 7  | N/D | Group 4 | 60    | NA   |
| MB30     | M  | 59 | C   | SHH | 0       | U   | MB57     | F  | 5  | C   | Group 4 | 60    | NA   |
| MB33     | M  | 2  | L/A | SHH | 0       | NA  | MB9      | M  | 14  | C   | Group 4 | 70    | NA   |
| MB40     | F  | 1  | N/D | SHH | 0       | NA  | MB23     | M  | 6  | L/A | Group 4 | 70    | U    |
| MB48     | M  | 7  | C   | SHH | 0       | NA  | MB34     | M  | 4  | EN  | Group 4 | 70    | NA   |
| MB51     | M  | 35 | N/D | SHH | 0       | NA  | MB24     | M  | 7  | C   | Group 4 | NA    | NA   |
| MB6      | M  | 4  | EN  | SHH | 5       | NA  | MB63     | M  | 6  | C   | Group 4 | NA    | NA   |
| MB72     | F  | 10 | N/D | SHH | 15      | NA  | MB69     | M  | 5  | C   | Group 4 | NA    | NA   |
| MB5      | M  | 6  | N/D | SHH | 20      | U   | MB70     | F  | 13 | L/A | Group 4 | NA    | NA   |
| MB16     | M  | 38 | N/D | SHH | 20      | U   | MB77     | F  | 16 | C   | NA    | 0     | U    |
| MB43     | F  | 6  | L/A | SHH | 20      | NA  | MB81     | M  | 10  | C   | NA    | 0     | Me   |
| MB12     | F  | 15 | C   | SHH | 60      | U   | MB82     | F  | 1.5 | C   | NA    | 0     | U    |
| MB61     | F  | 30 | L/A | SHH | NA      | NA  | MB86     | F  | 3  | C   | NA    | 0     | U    |
| MB8      | F  | 12 | C   | Group 3 | 0 | U | MB87     | M  | 3  | N/D | NA    | 0     | U    |
| MB14     | F  | 6  | L/A | Group 3 | 0 | U | MB88     | M  | 13 | N/D | NA    | 0     | U    |
| MB17     | M  | 24 | N/D | Group 3 | 0 | U | MB89     | M  | 9  | C   | NA    | 0     | U    |
| MB31     | M  | 17 | C   | Group 3 | 0 | NA | MB90     | M  | 3  | C   | NA    | 0     | Me   |
| MB35     | M  | 7  | C   | Group 3 | 0 | NA | MB92     | M  | 35 | L/A | NA    | 0     | U    |
| MB37     | M  | 5  | C   | Group 3 | 0 | NA | MB94     | F  | 12 | C   | NA    | 0     | U    |
| MB41     | F  | 7  | C   | Group 3 | 0 | NA | MB95     | F  | 5  | EN  | NA    | 0     | U    |
| MB50     | F  | 12 | N/D | Group 3 | 0 | NA | MB101    | F  | 5  | C   | NA    | 0     | U    |
| MB54     | F  | 11 | C   | Group 3 | 0 | NA | MB104    | M  | 3  | C   | NA    | 0     | Me   |
| MB47     | M  | 27 | C   | Group 3 | 20 | NA | MB106    | F  | 13 | EN  | NA    | 0     | U    |
| MB33     | F  | 10 | N/D | Group 3 | 50 | NA | MB27     | M  | 7  | L/A | NA    | 5     | U    |
| MB10     | M  | 16 | EN  | Group 3 | 60 | U  | MB80     | F  | 14 | N/D | NA    | 5     | Me   |
| MB56     | M  | 2  | N/D | Group 3 | 60 | NA | MB91     | M  | 41 | EN  | NA    | 5     | Me   |
| MB49     | F  | 6  | C   | Group 3 | 70 | NA | MB103    | F  | 17 | C   | NA    | 5     | Me   |
| MB7      | M  | 21 | C   | Group 3 | NA | NA | MB84     | M  | 7  | C   | NA    | 10    | U    |
| MB28     | M  | 7  | C   | Group 3 | NA | NA | MB93     | M  | 8  | N/D | NA    | 20    | U    |
| MB62     | M  | 4  | C   | Group 3 | NA | NA | MB98     | F  | 10 | EN  | NA    | 20    | Me   |
| MB67     | M  | 13 | C   | Group 3 | NA | NA | MB102    | F  | 9  | N/D | NA    | 20    | U    |
| MB59     | F  | 5  | N/D | Group 4 | 0  | NA | MB96     | F  | 8  | N/D | NA    | 25    | U    |
| MB65     | F  | 6  | L/A | Group 4 | 0  | NA | MB25     | M  | 5  | C   | NA    | 30    | NA   |
| MB46     | M  | 6  | EN  | Group 4 | 20 | NA | MB83     | M  | 2  | C   | NA    | 30    | U    |
| MB55     | F  | 40 | N/D | Group 4 | 70 | NA | MB85     | M  | 16 | N/D | NA    | 30    | U    |
| MB4      | F  | 16 | C   | Group 4 | 0  | NA | MB97     | F  | 6  | N/D | NA    | 30    | U    |

(Continues)
The methylation status of SNCA promoter in MB cell lines and 51 primary MBs was evaluated with methylation-specific PCR (MSP) and pyrosequencing (PyroMark Q96; Qiagen, Hilden, Germany) analyses (Table S1). CpGenome universal methylated DNA and universal unmethylated DNA (Millipore, Billerica, MA, USA) were used as methylation and unmethylation controls, respectively. Normal cerebellar tissues were obtained from postmortem brain tissue of four children. All experiments were repeated at least twice.

2.7 | Knockdown and overexpression of SNCA in MB cells

Daoy, D283, and D341 cells were seeded in 6-well plates at a cell density of $4 \times 10^4$. Transfection of three SNCA siRNAs (siRNA1, siRNA2, or siRNA3) or siRNA negative control at a final concentration of 20 μmol/L was carried out with Chemifect transfection reagent (Feng Rui, China) according to the manufacturer’s recommendations. Transfection of SNCA wild-type plasmid (GV219-SNCA-wt) and negative control plasmid (GV219) were carried out using Neofect reagent (Lingke Chuangzhi, China) according to the manufacturer’s recommendation. Both of the plasmids were given as gifts from Professor Jing Zhang’s Parkinson’s Disease Laboratory (University of Washington, Seattle, WA, USA). Cells were harvested 24 h after knockdown and overexpression of SNCA, followed by quantitative RT-PCR and Western blot analyses for three times, respectively.

2.8 | Western blot assay to detect α-synuclein expression in MB cells

Western blot assay was carried out using α-synuclein primary mAb (1:1000; 610787; BD Biosciences) to detect the α-synuclein

### Table 1 (Continued)

| Case no. | G | A | His | Mol | IHC (%) | MSP | Case no. | G | A | His | Mol | IHC (%) | MSP |
|----------|---|---|-----|-----|--------|-----|----------|---|---|-----|-----|--------|-----|
| MB19     | M | 11| C   | Group 4 | 0 | U | MB100 | F | 6 | N/D | NA | 30   | U   |
| MB45     | F | 10| C   | Group 4 | 0 | NA | MB76  | M | 19| N/D | NA | 50   | U   |
| MB53     | M | 7 | C   | Group 4 | 0 | NA | MB79  | F | 13| C   | NA | 50   | Me  |
| MB60     | F | 10| N/D | Group 4 | 0 | NA | MB26  | M | 4 | N/D | NA | 70   | NA  |
| MB21     | M | 10| C   | Group 4 | 5 | Me | MB99  | F | 32| C   | NA | 70   | U   |
| MB22     | M | 10| N/D | Group 4 | 5 | U | MB105 | M | 8 | C   | NA | 70   | U   |
| MB32     | M | 8 | C   | Group 4 | 5 | NA | MB78  | F | 6 | EN | NA | 80   | U   |

A, age (years); C, classic; EN, extensive nodular; F, female; G, gender; His, Histologic subtype; IHC, positive immunohistochemical staining of α-synuclein; L/A, large cell/anaplastic; M, male; Me, methylation; Mol, molecular subgroup; MSP, methylation-specific PCR detection of SNCA promoter; NA, not available; N/D, nodular/desmoplastic; U, unmethylation.
expression in MB cells (Daoy, D283, and D341) before and after transfection of three SNCA siRNAs and GV219-SNCA plasmid. β-Actin primary mAb (1:1000, mAbcam 8226; Abcam, Cambridge, MA, USA) was used as the internal control.

2.9 | Real-time PCR analysis of SNCA mRNA expression after treatment in MB cell lines

First-strand synthesis of cDNA used 5× all-in-one RT-mastermix (G486; Applied Biological Materials, Canada) following the manufacturer’s instructions. For the qRT–PCR reaction, EvaGreen 2× qPCR mastermix-LR (G486; Applied Biological Materials, Richmond, Canada) was used. The protocol was optimized for the 3000p reader (Applied Biosystems, Life Technology). The relative gene expression was calculated for the gene of interest by using the ΔACT method, where cycle threshold values were normalized to β-catenin (Table S1).

2.10 | Wound healing and invasion assay of MB cells

Daoy cells were grown to 70-80% confluence. A linear wound was made by scraping a non-opening Pasteur pipette across the confluent cell layer 24 h after transfection of siRNA1, siRNA2, and siRNA3. Cells were washed twice to remove detached cells and debris. The size of these wounds was observed and measured 24 h after scraping. Cell invasion assays was monitored using the Transwell chamber assay. The SNCA siRNAs and GV219-SNCA-wt plasmid-transfected Daoy cells (1 × 10^5 cells) were plated on upper chambers with 8-µm Transwell filters coated with 25 µL Matrigel (1:3; Corning, Corning, NY, USA). The cells were induced to invade towards medium containing 10% FBS in the lower chambers for 24 h. The invaded cells were fixed, stained with 0.1% crystal violet, and analyzed using a bright field microscope. All functional experiments were repeated three times.

### Table 1

| Gene   | Molecular subtype | AUC    | SE    | Sensitivity (%) | Specificity (%) | P-value |
|--------|-------------------|--------|-------|-----------------|-----------------|---------|
| PDGFRα | WNT               | 0.8594 | 0.0994| 87.50           | 82.81           | 0.0010  |
| FGFR1  | WNT               | 0.9692 | 0.0199| 100.00          | 93.85           | <0.0001 |
| ALK    | WNT               | 0.9626 | 0.0323| 85.71           | 96.92           | <0.0001 |
| CCND1  | SHH               | 0.8259 | 0.0578| 81.25           | 73.21           | <0.0001 |
| MYCN   | SHH               | 0.9386 | 0.0273| 100.00          | 76.79           | <0.0001 |
| TP53   | SHH               | 0.8371 | 0.0533| 81.25           | 82.14           | <0.0001 |
| GLI1   | SHH               | 0.9900 | 0.0082| 100.00          | 91.07           | <0.0001 |
| MYC    | Group 3           | 0.9033 | 0.0373| 83.33           | 87.04           | <0.0001 |
| SNCAIP | Group 4           | 0.9103 | 0.0325| 83.87           | 82.93           | <0.0001 |
| SNCA   | Group 4           | 0.8875 | 0.0385| 87.10           | 80.49           | <0.0001 |

**FIGURE 2** (A) Receiver operating characteristic (ROC) analysis of 10 signature genes assigned to subgroups of medulloblastoma. AUC, area under the ROC curve. (B) ROC curves were generated to evaluate the accuracy of 10 signature genes as diagnostic markers to discriminate different subgroups of tumors. Based on the RNA expression values from the NanoString analysis, each gene in the corresponding subgroup had a higher expression level compared with the other three groups.
Apoptosis induction was confirmed by Annexin V–FITC and propidium iodide (PI) detection kit (Jia Mei, China) measured by flow cytometry following the manufacturer’s recommended protocol. Flow cytometry analysis was carried out on a BD FACS Canto II instrument (BD Biosciences, Franklin Lakes, NJ, USA). Data were collected with DIVA software (BD Biosciences, Franklin Lakes) and analyzed with FlowJo software (Tree Star, Ashland, OR, USA) using appropriate controls and gates. Annexin V-positive and PI-negative cells were

2.11 Apoptosis and cell proliferation assay

Apoptosis induction was confirmed by Annexin V–FITC and propidium iodide (PI) detection kit (Jia Mei, China) measured by flow cytometry following the manufacturer’s recommended protocol. Flow cytometry analysis was carried out on a BD FACS Canto II instrument (BD Biosciences, Franklin Lakes, NJ, USA). Data were collected with DIVA software (BD Biosciences, Franklin Lakes) and analyzed with FlowJo software (Tree Star, Ashland, OR, USA) using appropriate controls and gates. Annexin V-positive and PI-negative cells were
in early apoptosis, and cells positive for both Annexin V and PI were either in the late stages of apoptosis or were already dead. Cells transfected by empty vector and normal cells were used as controls. Cell proliferation was detected by CCK-8 (Life Science, USA) according to the manufacturer’s instructions.

2.12 Statistical analysis

All statistical analyses was undertaken using the SPSS 20.0 statistical software package. Results are presented as mean ± SEM. Student’s t-test was used to determine statistical differences between subgroups. Analysis of variance was used to evaluate the relationship between SNCA expression and clinicopathologic characteristics. Spearman’s analysis was used to evaluate the correlation between RNA and protein levels of SNCA expression in MB tumors, as well as the consistency of SNCA and SNCAIP expression in these primary tumors. Other results were evaluated with the independent samples t-test. P-values <.05 were considered to be statistically significant.

3 RESULTS

3.1 Subgroup assignment of MB and novel signature genes specific to each group identified by NanoString assay

Our previous study validated the reliability of the NanoString assay for MB subgrouping in 45 Chinese patients using the 22 classic gene CodeSet with the NanoString nCounter Analysis System (NanoString Technologies). To further integrate more subgroup-specific genes recruited by the 2016 WHO classification and other studies using various techniques into one platform, and to find therapeutic targets in the current study, we assigned molecular subgroups in 72 primary
MB with a larger custom-designed CodeSet, which contained 33 genes including 11 additional candidate subgroup signature genes. Current results showed that the MB subgroup could be predicted in a larger cohort of tumors (96%, 72/75) by non-hierarchical clustering analysis, with 11.11% (8/72) of tumors subgrouped as WNT, 20.83% (15/72) as SHH, 25% (18/72) as Group 3, and 43.06% (31/72) as Group 4 (Table 1, Figure 1). Analysis and normalization of raw NanoString data using nSolver Analysis Software version 2.5 (NanoString Technologies) showed a “quantification control (QC) flag” in 3/75 (4%) of cases (MB25, MB26, and MB27), which means our current NanoString assay was unable to provide a high confidence for subgroup assignment in these three cases (Table S2).

Among the 11 candidate signature genes, 10 were shown to have higher expression and a close relationship with different subgroups based on the classic panel gene assignment: PDGFRA, FGFR1, and ALK are associated with the WNT group; CCND1, MYCN, TP53, and GLI1 are associated with the SHH group; MYC is associated with Group 3; and SNCAIP and SNCA are associated with Group 4 (Figure 1).

3.2 Receiver operating characteristic curves of 10 newly identified subtyping genes

To evaluate the accuracy of these 10 genes as diagnostic markers to discriminate different subgroup tumors, receiver operating characteristic (ROC) curves were generated based on the higher RNA expression values from the NanoString analysis for each gene in the corresponding subgroup compared with the other three groups. The area under the ROC curves were: 0.8594, 0.9692, and 0.9626 for PDGFRA, FGFR1, and ALK in the WNT group, respectively; 0.8259, 0.9386, 0.8371, and 0.9900 for CCND1, MYCN, TP53, and GLI1 in the SHH group, respectively; 0.9033 for MYC in Group 3; and 0.9103 and 0.8875 for SNCAIP and SNCA in Group 4, respectively (Figure 2). Among these genes, SNCA is reported for the first time to be related to Group 4 MB, with high sensitivity (87.1%) and high specificity (80.49%; Figure 2A). The expression of SNCA in Group 4 on the RNA level was significantly higher than in WNT, SHH, and Group 3 (P < .0001; Figure 3), indicating that SNCA is a diagnostic marker with high sensitivity and specificity for subtyping MB on the RNA level.

3.3 Alpha-synuclein expression and its association with MB subgroups

To illustrate protein expression of α-synuclein encoded by SNCA in MB, IHC staining was undertaken in 93 MBs, and showed cytoplasmic and/or nuclear staining in differing proportions of the tumor area (Table 1; Figure 4). Among these MBs, 59 cases have been detected by the NanoString platform and were assigned with molecular subgroups (Table 1). The proportions of α-synuclein immunoreactivity in Group 4 was significantly higher compared with WNT and SHH groups (P = .0413 and .0381, respectively, t-test; Table 2, Figure 3B). It was also higher in Group 4 (with means of
27.62% ± 5.932%, n = 21) than that of Group 3 (with means of 19.44% ± 6.641%, n = 18), although the difference was not statistically significant in our cohort (P = .3632, t-test; Figure 3B). The SNCA gene expression on RNA and protein levels showed significant correlation (P < .0001, $R^2 = 0.3256$; Table 2, Figure 3C). RNA expression of SNCA was also closely related with that of SNCAIP, based on our NanoString data (P < .0001; Figure S1). Both of these molecules are specific markers with relatively high expression level in Group 4 MBs (Figure 2).

### 3.4 SNCA promoter methylation status in MB

Previous studies have shown that expression of SNCA is regulated by hypermethylation of the CpG island in its promoter region in various human cancers. Demethylation drug treatment in MB cells showed reversed expression of this gene, suggesting that the silenced expression of SNCA might be due to epigenetic regulation, including DNA hypermethylation (Figure 5A). To analyze the methylation status of the SNCA promoter CpG island in MB, three MB cell lines (Daoy, D283, and D341) and 51 primary tumors, for which DNA was available, were evaluated with MSP and pyrosequencing. Hypermethylation was observed in D283 and D341 cells as well as in 21.57% (11/51) of primary MB by MSP (Figure 5B). No methylation was detected in Daoy cells. An unmethylated band was detected in all cell lines and primary tumors, including D283 and D341 cells and in the hypermethylated primary MBs, indicating that hypermethylation in all of these tumors is incomplete. This result is consistent with our data from pyrosequencing analyses showing the frequency of hypermethylation is rather low in some CpG sites of the promoter region (~5%; Figure 5C), implying that epigenetic mechanisms other than DNA hypermethylation might play the key role in the regulation of SNCA expression (e.g. histone modification).

### 3.5 Capacity for migration and invasion in MB cells after knockdown and overexpression of α-synuclein, respectively

To explore the function of SNCA in MB cells, specific knockdown assays by siRNA transfection were carried out. Expression of SNCA was inhibited by siRNA (Figure 6). After transfection, the invasion ability of MB was significantly increased compared with the negative control. In contrast, overexpression of SNCA can decrease the invasion ability (Figure 7A). Wound healing assays showed that the migration ability was also increased after transfection of SNCA siRNA (Figure 7B).

### 3.6 Cell apoptotic and proliferation ability

To evaluate the effect of SNCA on apoptosis in MB cells, the Annexin V/PI detection assay was carried out (Figure 8). The
proportions of MB cells in early apoptosis and late stages of apoptosis, or already dead, were significantly higher than those of the normal cells and negative control ($P < .0001$). There was no significant difference before or after overexpression of SNCA in tumor cell proliferation (Figure S2), indicating that SNCA can improve the apoptotic activity of MB cells rather than cell proliferation.

4 | DISCUSSION

In the current study, novel subtype-specific diagnostic and/or therapeutic markers for each subgroup of MB, especially for Group 4, the largest group, were explored. SNCA was identified for the first time as the signature marker in Group 4 with high specificity and sensitivity. Regulation mechanism and functional studies were undertaken, focused on this gene. Some well-known subgroup-specific biomarkers revealed by various techniques and included in the new WHO classification, such as P53, NMYC, and MYC, were also integrated into our platform to improve clinical testing efficiency.

It is well known that increased expression of SNCA is closely correlated with increased risk of developing Parkinson’s disease (PD). Recently, it was reported that polymorphism in the SNCA gene is associated with PD phenotype. Non-viral vectors that can deliver siRNA against SNCA has been developed and can prevent PD-like symptoms both in vitro and in vivo, indicating that SNCA can be the potential target of gene therapy. Co-expression of α-synuclein and synphilin-1, which are encoded by SNCA and SNCAIP, respectively, favor the formation of Lewy bodies in the brain of patients with PD. Interestingly, the expression of α-synuclein could also be identified diffusely in tumors showing neuronal differentiation, including MB. Although the duplication of SNCAIP has been reported to be a somatic event highly specific to Group 4 MB, so far the relationship between SNCA and MB subtype has not been clarified. Based on the present data from subtyping, our study then focused on the SNCA gene in the largest subgroup of MB.

The RNA expression level of SNCA in Group 4 detected in the current study was significantly higher than each of the other three subgroups, and the area under the ROC curve was rather high,
indicating SNCA is a diagnostic marker for Group 4 MB with high sensitivity and specificity on the mRNA level. In addition, α-synuclein protein expression in MB showed significantly higher in the proportions of α-synuclein immunoreactivity in Group 4 compared with WNT and SHH groups. The protein expression level in Group 4 was also higher than that of Group 3, although the difference was not significant, which might be due to the limited case numbers. SNCA mRNA expression level and the proportion of positive staining for α-synuclein protein showed statistically significant correlation, supporting that SNCA could serve as a marker in MB subtyping not only on the RNA level but also on the protein level.

It has been reported that SNCA expression is regulated by epigenetic mechanisms in a series of human cancers, including cholangiocarcinoma, colorectal cancer, and non-Hodgkin’s lymphoma. Bethge et al reported that SNCA methylation might be suitable for early detection and monitoring of non-Hodgkin’s lymphoma. In our cohort, demethylation treatment could reverse the gene’s expression on the mRNA level in all three MB cell lines. Hypermethylation could be detected in some CpG sites of the promoter region, but the frequency of other CpG sites was rather low, shown by pyrosequencing analysis. That may explain the poor correlation between DNA methylation status from MSP and gene expression analyses (Table 2), indicating that SNCA expression might be regulated indirectly by epigenetic mechanisms rather than DNA methylation, such as histone modification.

Alpha-synuclein aggregation was recently identified as essential to apoptotic neurons in PD. It was also observed to be downregulated by miR-153-3p and miR-205-5p in neuroblastoma cells, suggesting its potential as a tumor suppressor. In the present study, the anti-apoptotic function and invasion ability of MB cells, rather than cell proliferation, were increased after SNCA siRNA transfection, but decreased after overexpression of the gene, indicating the potential tumor suppressor function of SNCA in MB. Expression of SNCA was observed to have a close relationship with SNCAIP in MB (Figure S1), which has been reported to be related with various tumors. Future study will be required to understand the mechanism of the synergetic effect between SNCA and SNCAIP on MB tumor invasion as well as apoptosis in vitro and in vivo.

Recently, each subgroup of MB was split further based on comprehensive molecular profiling that can improve disease risk stratification and inform treatment decisions. In order to integrate more diagnostic markers and candidates for therapeutic targets of this tumor into one testing platform, we also investigated the correlation of several additional candidate signature genes with subgroups of MB. Some of these markers, such as ALK in the WNT group, TP53, NMYC, and GLI2 in the SHH group, MYC in Group 3, and SNCAIP in Group 4, have been identified in various studies using different methods, which strongly supports the results from the NanoString assay in the current study. Furthermore, we identified several novel MB subgroup markers, including FGFR1 and PDGFRA in the WNT group and CCND1 in the SHH group. These three genes have all been reported to be potential targets for gene therapy in various tumors. It is hoped that further exploration in vitro and in vivo will reveal their therapeutic value in specific subtypes of MB. PDGFRA was assigned to the WNT group in the present cohort, whereas it has been classified to the SHH group in another report. The inconsistency between different studies could be due to variations from different races or technique platforms, which need larger cohorts of samples to clarify.

In summary, we showed for the first time that SNCA is a Group 4-related diagnostic marker with both high sensitivity and specificity in MB. SNCA expression might be regulated indirectly with epigenetic mechanisms rather than DNA hypermethylation. Further survival analyses will clarify its prognostic value for MB patients. In addition, the NanoString gene expression assay enriched with the 33 custom-designed gene CodeSet showed excellent efficiency for MB subgroup assignment and potential biomarker identification. Our knowledge of MB in this study will shed new light on clinical usage of molecular subtyping of MB and, ultimately, benefit the patients.

ACKNOWLEDGMENTS

This work was supported by the National Natural Science Foundation of China (Grant Nos. 81101900 and 30540008) and the Clinicopathologic Innovation Fund from Peking University Third Hospital, Peking University Health Science Center (to Qing Chang).

CONFLICT OF INTEREST

The authors have no conflict of interest.

ORCID

Qing Chang http://orcid.org/0000-0001-5138-8760

REFERENCES

1. Kim SY, Sung KW, Hah JO, et al. Reduced-dose craniospinal radiotherapy followed by high-dose chemotherapy and autologous stem cell rescue for children with newly diagnosed high-risk medulloblastoma or supratentorial primitive neuroectodermal tumor. Korean J Hematol. 2010;45:120-126.
2. Packer RJ, Gajjar A, Vezina G, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol. 2006;24:4202-4208.
3. Louis DN, Perry A, Reifenberger G, et al. The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131:903-820.
4. Kool M, Korshunov A, Remke M, et al. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol. 2012;123:473-484.
5. Li Y, Jiang T, Shao L, et al. Mir-449a, a potential diagnostic biomarker for WNT group of medulloblastoma. J Neurooncol. 2016;129:423-431.
6. Taylor MD, Northcott PA, Korshunov A, et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol. 2012;123:465-472.
7. Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol. 2011;29:1408-1414.
20. Faria CC, Golbourn BJ, Dubuc AM, et al. Foretinib is effective therapeutic targets for metastatic disease. Lancet Oncol. 2013;14:1200-1207.

21. Gravina GL, Mancini A, Sanita P, et al. Erratum to: KPT-330, a potent selective inhibitor of PDK1, shows antitumor effects modulating the expression of cyclin D1 and survivin in prostate cancer models. BMC Cancer. 2016;16:8.

22. Kang M. FGFR inhibitors: effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review). Int J Mol Med. 2016;38:3-15.

23. Li M, Lockwood W, Zielenska M, et al. Multiple CDK/CYCLIND genes are amplified in medulloblastoma and supratentorial primitive neuroectodermal brain tumor. Cancer Genet. 2012;205:220-231.

24. MacDonald TJ, Brown KM, LaFleur B, et al. Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat Genet. 2001;29:143-152.

25. Epple LM, Griffiths SG, Dechovskaia AM, et al. Medulloblastoma exosome proteomics yield functional roles for extracellular vesicles. PLoS One. 2012;7:e42064.

26. Fung KM, Rorke LB, Giasson B, Lee VM, Trojanowski JQ. Expression of alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Acta Neuropathol. 2001;101:143-152.

27. Shao LW, Pan Y, Qi XL, et al. ATRX loss in adult supratentorial diffuse astrocytomas correlates with p53 over expression and IDH1 mutation and predicts better outcome in p53 accumulated patients. Histol Histopathol. 2016;31:103-114.